{"title":"奎尼丁在连续流动腹膜透析中的药代动力学。","authors":"T W Chin, S Pancorbo, C Comty","doi":"10.3109/08860228109076030","DOIUrl":null,"url":null,"abstract":"<p><p>The clearance of quinidine was evaluated in a patient undergoing continuous ambulatory peritoneal dialysis (CAPD). The dialysis clearance of quinidine was 0.793 ml/min which represented only 0.61% of the total body clearance (154.21 ml/min) of the drug. The elimination half-life of quinidine was 5.44 hours. Based on our results, dosage adjustment of quinidine does not appear to be necessary for patients undergoing CAPD.</p>","PeriodicalId":79208,"journal":{"name":"Clinical and experimental dialysis and apheresis","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/08860228109076030","citationCount":"8","resultStr":"{\"title\":\"Quinidine pharmacokinetics in continuous ambulatory peritoneal dialysis.\",\"authors\":\"T W Chin, S Pancorbo, C Comty\",\"doi\":\"10.3109/08860228109076030\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The clearance of quinidine was evaluated in a patient undergoing continuous ambulatory peritoneal dialysis (CAPD). The dialysis clearance of quinidine was 0.793 ml/min which represented only 0.61% of the total body clearance (154.21 ml/min) of the drug. The elimination half-life of quinidine was 5.44 hours. Based on our results, dosage adjustment of quinidine does not appear to be necessary for patients undergoing CAPD.</p>\",\"PeriodicalId\":79208,\"journal\":{\"name\":\"Clinical and experimental dialysis and apheresis\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1981-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.3109/08860228109076030\",\"citationCount\":\"8\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and experimental dialysis and apheresis\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3109/08860228109076030\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and experimental dialysis and apheresis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3109/08860228109076030","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Quinidine pharmacokinetics in continuous ambulatory peritoneal dialysis.
The clearance of quinidine was evaluated in a patient undergoing continuous ambulatory peritoneal dialysis (CAPD). The dialysis clearance of quinidine was 0.793 ml/min which represented only 0.61% of the total body clearance (154.21 ml/min) of the drug. The elimination half-life of quinidine was 5.44 hours. Based on our results, dosage adjustment of quinidine does not appear to be necessary for patients undergoing CAPD.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
